These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19770796)

  • 21. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet.
    Freye E; Levy JV; Braun D
    Pain Pract; 2007 Dec; 7(4):324-31. PubMed ID: 17986159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of PF-402, sustained-release morphine capsule, in cancer patients with pain].
    Ogawa H; Hiraga K; Takeda F
    Masui; 1998 Jul; 47(7):817-23. PubMed ID: 9720327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ALERRT
    Cone EJ; Buchhalter AR; Lindhardt K; Elhauge T; Dayno JM
    Am J Drug Alcohol Abuse; 2017 May; 43(3):291-298. PubMed ID: 28448223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
    Currow DC; Plummer JL; Cooney NJ; Gorman D; Glare PA
    J Pain Symptom Manage; 2007 Jul; 34(1):17-23. PubMed ID: 17601560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of ethanol on the in vitro and in vivo drug release from some sustained release tablets (author's transl)].
    Frömming KH; Topaloglu Y
    Arzneimittelforschung; 1975; 25(12):1958-64. PubMed ID: 3188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of sustained-release morphine in a hospice setting.
    Sherman LM
    Pharmatherapeutica; 1987; 5(2):99-102. PubMed ID: 3659062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
    Ross EL; Hahn K
    Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on dissolution in vitro of Zhike Pingchuan sustained-release tablets].
    Li X; Feng Z; Huo W; Li Y; Wang B; Zhu S
    Zhongguo Zhong Yao Za Zhi; 2009 May; 34(10):1216-9. PubMed ID: 19673379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effective analysis of rotation from sustained-release morphine tablet to transdermal fentanyl of matrix type or sustained-release oxycodone tablet].
    Ise Y; Wako T; Miura Y; Katayama S; Shimizu H
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2599-603. PubMed ID: 20009462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis.
    Palm S; Moenig H; Maier C
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):269-73. PubMed ID: 9228653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normal-release oral morphine starting dose in cancer patients with pain.
    Ripamonti CI; Campa T; Fagnoni E; Brunelli C; Luzzani M; Maltoni M; De Conno F;
    Clin J Pain; 2009 Jun; 25(5):386-90. PubMed ID: 19454871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses.
    Bass J; Shepard KV; Lee JW; Hulse J
    J Clin Pharmacol; 1992 Nov; 32(11):1003-7. PubMed ID: 1474160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets.
    Kaiko RF; Fitzmartin RD; Thomas GB; Goldenheim PD
    Pharmacotherapy; 1992; 12(2):107-13. PubMed ID: 1570227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model.
    Christensen KS; Cohen AE; Mermelstein FH; Hamilton DA; McNicol E; Babul N; Carr DB
    Anesth Analg; 2008 Dec; 107(6):2018-24. PubMed ID: 19020153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
    Miner JR; Moore J; Gray RO; Skinner L; Biros MH
    Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
    Skak N; Elhauge T; Dayno JM; Lindhardt K
    J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.